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Peroxisome proliferator-activated receptor-γ (PPARγ) and retinoic acid X-receptor (RXR) heterodimer, which regulates cell
growth and diﬀerentiation, represses the TGFβ1 gene that encodes for the protein involved in cancer biology. This review will
introduce the novel mechanism associated with the inhibition of the TGFβ1g e n eb yP P A R γ activation, which regulates the
dephosphorylation of Zf9 transcription factor. Pharmacological manipulation of TGFβ1b yP P A R γ activators can be applied
for treating TGFβ1-induced pathophysiologic disorders such as cancer metastasis and ﬁbrosis. In this article, we will discuss the
opposing eﬀects of TGFβ on tumor growth and metastasis, and address the signaling pathways regulated by PPARγ for tumor
progression and suppression.
Copyright © 2008 Chang Ho Lee et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptor-γ (PPARγ)a sa
ligand-activated transcription factor belongs to the members
of nuclear hormone receptor superfamily. PPARγ is impli-
cated in a wide variety of cellular functions, regulating the
expression of gene networks required for cell proliferation,
diﬀerentiation, morphogenesis, and metabolic homeostasis.
The transforming growth factor isoforms (TGFβ1, β2, and
β3)asthemembersoftheTGFβsuperfamilyareubiquitously
expressed cytokines [1, 2]. TGFβ exerts multiple functions
with diﬀerential expression pattern in organs: each form of
TGFβ has similar biological activities [3]. Among the TGFβ
forms, it is recognized that TGFβ1 plays a major role in the
regulation of cell proliferation and diﬀerentiation. In this
reviewpaper,wewilldiscusstheroleofPPARγ onTGFβgene
expression.
Accumulating evidences suggest that the interplay of
PPARγ and TGFβ contributes to the regulation of cell
proliferation, diﬀerentiation, and their associated cellular
functions. For instance, the interaction of PPARγ signaling
with the proteins aﬀected by the activation of TGFβ receptor
determines the outcome of the breast tumor progression [4].
Many studies have shown that agonist-induced activation
of PPARγ interferes with TGFβ/Smad-dependent or Smad-
independent signaling in diﬀerent cell types [5–12]. The
crosstalk between PPARγ and TGFβ can be achieved not
only by PPARγ-dependent modulation of the propagation
of TGFβ/TGFβ receptor-mediated signaling pathways, but
also by the regulation of TGFβ1 expression itself and TGFβ1-
inducibletargetgenes.Hence,suppressionofTGFβ signaling
by PPARγ could be counteracted by the inhibitory action of
TGFβ on the PPARγ-mediated signaling [13–15].
The TGFβ1 expression is regulated at multiple levels.
Diverse transcription factors are involved in the tran-
scriptional regulation of TGFβ gene expression and post-
translational modiﬁcation makes precursors bound with
TGFβ1 binding proteins mature to TGFβ molecule [16, 17].
T h er o l eo fP P A R γ activation in TGFβ1 gene repression has
been examined by the experiments using thiazolidinedione
PPARγ agonists [18, 19]. These studies on the regula-
tion of the TGFβ1 gene and the molecular interaction
of ligand-activated nuclear receptors for the activation of
responsible transcription factor(s) brought insights into2 PPAR Research
the transcriptional control mechanism. The research results
showed that PPARγ activation might transrepress the TGFβ
gene, interfering with TGFβ signaling and thereby altering
the expression of TGFβ-inducible target genes [18], substan-
tiating the fact that ligand activation of PPARγ modulates
TGFβ receptor-mediated gene regulation.
2. TGFβ AND CANCER CELL BIOLOGY
TGFβ1 exerts its diverse biological eﬀects by acting on dis-
tinct combinations of type I and type II receptors and
recruiting downstream signal transducers including Smads,
consequently regulating a group of target gene expression
responsible for a speciﬁc biological activity. Smad pro-
teins are classiﬁed into R-Smads (receptor-regulated Smads:
S m a d s1 ,2 ,3 ,5 ,a n d8 ) ,C o - S m a d s( c o m m o nm e d i a t o r
Smad: Smad 4), and I-Smads (inhibitory Smads: Smad 6 and
7), and these play roles as the transcriptional regulators for
the superfamily of TGFβ1-inducible target genes [1, 2, 20–
22]. Smad 2 and Smad 3 are the speciﬁc mediators of TGFβ1,
whereas Smad 1, Smad 5, and MADH6/Smad 9 are crucial
for bone morphogenic protein signaling [22]. In particular,
Smad 3 is involved in the TGFβ1 gene regulation, which is
crucial for the autocrine function of TGFβ1[ 23].
Following the activation of the TGFβ1r e c e p t o rb y
TGFβ1, TGFβ1-induced receptor kinase activation rapidly
phosphorylates Smads proteins and initiates formation of
functional oligomeric complexes. The resultant oligomeric
complex translocates to the nucleus to regulate target
gene expression. Brieﬂy, the type I TGFβ1 receptor kinase
phosphorylates serine residues at the C-terminal SSXS
motif in the MH2 domain of Smad 3 (or Smad 2) [24].
Phosphorylated Smad 3 (or Smad 2) forms an oligomeric
complex with Smad 4, which is crucial for the maximal
transcription of diverse TGFβ1-inducible target genes [25,
26]. The oligomeric complexes of Smad 3 (or Smad 2)
and Smad 4 recognize DNA binding element tetranucleotide
(CAGA) or GC-rich sequences, and several copies of which
are present in the promoter regions of many TGFβ1-
responsive genes such as plasminogen activator inhibitor-1
(PAI-1), α2(I) procollagen, and type VII collagen [25, 27].
It is well known that the protein products encoded from
thesegenespromotetheaccumulationofextracellularmatrix
and that abnormal accumulation of the proteins may lead
to ﬁbrosis, which represents a form of the epithelial to
mesenchymal transition (EMT).
Moreover, TGFβ1-activated kinase-1, a member of
MAPK kinase kinase family, activates its MAP kinase path-
ways [28, 29]. It is accepted that TGFβ1-activated ERK
pathway synergistically enhances Smad signaling of the
TGFβ1 receptor due to the positive cross talk between the
ERK and Smad pathways [22, 30]. Serine phosphorylation
of Smad 3/2, but not phosphorylation of the C-terminal
motif, was decreased by MEK-ERK inhibitors [31]. Smad
3/2 are diﬀerentially activated by TGFβ1 in hepatic stellate
cells as a result of the diﬀerential phosphorylations of the
Smads. Smad 3 plays a key role in TGFβ signaling, which
is strengthened by the observation that the loss of Smad 3
interfered with TGFβ1-mediated induction of target genes
[32, 33]. In addition, activation of CCAAT/enhancer binding
protein(C/EBP)β isalsoinvolvedintheinhibitionofTGFβ1
expression [34].
During the process of carcinogenesis, TGFβ action can
be either tumor suppressive or tumor promoting, depend-
ing on the stage of tumor development [35–37]. In an
experimental cell model, TGFβ could induce cell growth
arrest and promote apoptosis of carcinoma cells [1]. The
antiproliferative action of TGFβ in epithelial cells, for
example, is essentially attributed to the cell cycle arrest
and the apoptosis concomitantly induced. It is well known
that cell cycle arrest induced by TGFβ occurs at G1 phase
through enhancing transcription of cyclin-dependent kinase
inhibitors, p21Cip1/WAF and p15Ink4b, while suppressing the
induction of c-Myc, a progrowth transcription factor, and of
Id1–3, the inhibitors of diﬀerentiation [38–43]. In a model
of gastric adenocarinoma, TGFβ-mediated apoptosis con-
tributed to tumor suppression, which resulted from TGFβ-
induced caspase-8 activation [44]. Moreover, it has been
shown that TGFβ reduced the expression of antiapoptotic
Bcl-2 family members in prostate cancer cells [45].
By contrast, TGFβ may also lead to tumor cell prolifer-
ation as a consequence of EMT process [46–48], which is
a cellular phenomenon characterized by a loss of polarized
epithelial phenotype with transition to a mesenchymal or
more migratory phenotype. Studies have shown that diverse
signaling pathways are involved in the TGFβ-dependent
E M Tp r o c e s s .I n i t i a t i o no fE M Tb yT G F β receptor activation
ismediatedbyeitherSmad-dependentorSmad-independent
pathway [1, 49, 50]. Downstream of the TGFβ receptor
activation, the Smads activated by the TGFβ receptor
kinase promote transcription of the genes, which eventually
play crucial roles in the process of EMT. The responsible
transcription factors primarily include Snail, Slug, and LEF-
1[ 1]. In addition, TGFβ also activates the non-Smad
pathways, which include Ras, phosphatidylinositol 3-kinase
(PI3K), and Par 6. These molecules regulate the expression
of Snail and the activities of glycogen synthase kinase 3β
(GSK3β)a n dR h o A ,r e s p e c t i v e l y[ 51, 52], thereby enhancing
the process of EMT. It is now accepted that the EMT
phenomenon of primary cancer cells promoted by the action
of TGFβ may increase cancer metastasis.
TGFβ acts on tumor cells directly, playing a role in
cancer cell migration and invasion. Diverse TGFβ-mediated
signaling pathways are responsible for this process. In
glioblastoma cells, siRNA knockdowns of TGFβ1a n dT G F β2
resulted in the inhibition of cell motility or invasiveness
[53] .A sas a m et o k e n ,T G F β released from tumor tissues
might facilitate glioma cell migration and invasion via
an autocrine signaling [54]. Several lines of evidence also
support the concept that TGFβ-induced Smad signaling is
responsible for the invasiveness of cancer cells [55–58]. This
is explained in part by the TGFβ-dependent induction of
matrix metalloproteases, which are known to be responsible
for cell migration and invasion [55, 59–62]. Activation of
ERK and JNK by TGFβ and their association with focal
complexes may also contribute to cell migration, as shown
in the case of breast carcinoma [63]. Moreover, it has been
shown that the activation of p38 MAPK pathway by TGFβChang Ho Lee et al. 3
facilitated invasion of head and neck squamous epithelial
cells [61].
In addition to the double-edged eﬀects of TGFβ on
cancer cells, TGFβ may alter cancer growth by suppressing
the growth of multiple immune cells, which compromises
the overall immune functions. Studies have shown that the
proliferation and activity of T cells are suppressed by the
TGFβ blockade of IL-2 production and expression of T
cell eﬀector molecules [64–68]. Also, TGFβ attenuates the
activity of natural killer (NK) cells by inhibiting NK produc-
tion of interferon-γ (IFN-γ)[ 69, 70]. Another study showed
that TGFβ inhibited the antigen presentation function of
dendritic cells through suppressing the expression of MHC
c l a s sI Ia n dc o s t i m u l a t o rym o l e c u l e s[ 71]. All of these results
supportthealterationsbyTGFβ inimmunefunctions,which
would impair immune surveillance or attack against cancer
cells.
In summary, action of TGFβ1 on cancer cells switches
from tumor suppression to tumor promotion, depending
on the stage of tumor progression. For instance, during
the early phase of breast tumorigenesis, the TGFβ signal
inhibits primary tumor growth via cell growth arresting and
promoting apoptosis. However, at later stage, cancer cells
acquire a capacity to escape from the tumor suppressive
eﬀects of TGFβ1 via induction of EMT. Interestingly, the
aforementioned conﬂicting functions of TGFβ might go
through the same TGFβ receptor complex and the associated
signaling pathways involving Smad transcription factors [1].
Probably, there should be certain stage-dependent modi-
ﬁcations in cellular signaling system including changes in
receptor function and downstream Smad signaling cascades.
Taken together, it is concluded that TGFβ may not only
induce growth arrest of cancer cells, but also increase
cancer dissemination [1], supporting the concept that the
cytokine serves a dual function in tumor development and
progression (Figure 1).
3. PPARγ AND CANCER BIOLOGY
PPARγ hasbeenextensivelystudiedasananticancertargetin
preclinical and clinical settings [72]. The anticancer eﬀects
appeared to be cancer cell-speciﬁc. A knock-out or loss
of function mutation in PPARγ can be an important risk
factor for the incidence of cancer [73–75]. In this sense,
PPARγ has been considered as a novel target for designing
new anticancer drugs for chemotherapy. This is further
supported by the ﬁnding that PPARγ activators exert a
potent tumor-suppressing activity against various human
cancer cells [76–78] .A sam a t t e ro ff a c t ,P P A R γ activators
such as troglitazone and ciglitazone exert antiproliferative
activities in epithelial cancer cell lines or animal models,
which presumably results from the activation of PPARγ
receptor and the PPARγ receptor-dependent pathways [76,
79–83]. Nevertheless, other anticancer pathways have also
been recognized in association with PPARγ, which might
be PPARγ receptor-independent [84, 85]. Multiple PPARγ-
independent anticancer targets of PPARγ agonists have been
suggested in several cancer cell types. The mechanisms may
comprise a variety of pathways such as the blockade of
TGFβ
Cell growth
arrest
Apoptosis Epithelial to mesenchymal
transition (EMT)
Decreased tumor progression Cancer cell
dissemination
Anti-tumor eﬀect Metastasis of
cancer cells
Figure1:AschemeshowingtheopposingeﬀectsofTGFβontumor
growth and metastasis.
G1-S phase transition by inhibiting translation initiation
[86], activation of JNK-dependent cell death pathway [87],
induction of the early growth response-1 (Egr-1) gene [88],
inhibition of Bcl-xL and Bcl-2 function [85], counteracting
TGFβ r e l e a s eb yt u m o rc e l l s[ 54], and induction of cyclin-
dependent kinase inhibitor p21WAF1/CIP1 [89]. However, the
precise antiproliferative mechanisms of the PPARγ agonists
remain to be further studied. On the contrary, there are also
other reports available on the opposite eﬀects showing that
PPARγ signaling promoted carcinogenesis [90, 91].
It should be noted that the antitumor eﬀects of PPARγ
may be explained at least in two diﬀerent ways. One
mechanisminvolvescellgrowthregulation[4],whichshould
be further clariﬁed, whereas the other mechanism includes
cancer chemopreventive eﬀects mediated by the induction
of antioxidant enzymes [92]. It is well recognized that
PPARγ aﬀects cell survival, growth, and diﬀerentiation by
acting on the peroxisomal proliferator-response element
(PPRE), thereby modulating an expression of a group of
genes controlling cell growth and diﬀerentiation pathways
[93, 94]. The PPARγ homodimer and PPARγ-retinoic acid
Xr e c e p t o r( R X R )α heterodimer have the speciﬁcities of
DNA-binding with preferential binding of the latter to DR1,
which is a PPRE DNA binding site. SRC-1 is a coactivator
of PPARγ [95]. Binding of the ligand-activated PPARγ-
RXRα heterodimer to its DNA binding sites stimulates the
interaction between PPARγ-RXRα and p160/SRC-1 [95].
A number of studies support the concept that can-
cer chemoprevention is accomplished by the induction of
antioxidant enzymes. The results from our laboratories
indicated that oltipraz and ﬂavonoids as potential cancer
chemopreventive agents activate C/EBPβ in the antioxidant
genes such as glutathione S-transferase (GST) A2 [96, 97]. In
addition, treatments of cells with PPARγ activators induced
the nuclear translocation of NF-E2-related factor 2 (Nrf2)
and C/EBPβ, and activating Nrf2 and C/EBPβ bindings to
theantioxidantresponseelement(ARE)andC/EBPresponse
elements, respectively [92]. Moreover, the Nrf2 and C/EBPβ
genes contain PPRE sites, which account for the induction4 PPAR Research
of the target antioxidant proteins by PPARγ activators. Both
the ARE and the C/EBP binding site have crucial roles in
transactivating the GSTA2 gene by PPARγ and RXR ligands
[92]. Therefore, Nrf2 and/or C/EBPβ inductions(s) via the
PPARγ and RXRα heterodimer binding to the PPREs in the
promoter regions of the target genes contribute(s) to the
antioxidant capacity of cells (e.g., GSTA2).
A result of our previous study indicated that speciﬁc
mutations of these nuclear binding sites in the GSTA2
promoter, which are present as a three-PPRE cluster, caused
the complete loss of its responsiveness to PPARγ activators
[92]. All of the putative PPRE sites comprising DR1 were
functionally active. Therefore, the binding of the activating
PPARγ-RXR heterodimer to all of the PPRE sites appeared
to be crucial for the inducible gene activation, showing
that the PPAR binding site cluster is the functionally active
PPRE-responsive enhancer module (PPREM) [92]. This
study on the regulation of gene expression by the PPARγ-
RXR heterodimer at the promoter containing multiple DR1
elements brought additional insight into the transcrip-
tional control mechanism of the antioxidant enzymes. The
identiﬁed molecular mechanism would shed light on the
contribution of cell viability and cancer chemoprevention as
a consequence of the induction of antioxidant targets genes
by PPARγ activators.
4. TGFβ REGULATION BY PPARγ-RXR
AND CELL SIGNALING
Activation of the PPARγ-RXR heterodimer represses the
TGFβ1 gene through dephosphorylation of a transcription
factor called zinc ﬁnger transcription factor-9 (Zf9), which
has been shown to be induced by phosphatase and tensin
homolog deleted on chromosome (PTEN)-mediated p70
ribosomal S6 kinase-1 (S6K1) inhibition [18]. Because
RXRs are modular proteins with a highly conserved central
DNA binding domain and a less conserved ligand binding
domain [98], activation of the PPARγ and RXR heterodimer
contributes to the gene regulation. The role of PPARγ in
repression of the TGFβ1g e n ew a sf u r t h e re v i d e n c e db y
the eﬀects of thiazolidinediones, and also by the reversal
of TGFβ1 repression by the dominant negative mutants,
supporting to the novel aspect that PPARγ activation
contributes to TGFβ1 gene repression and that RXRα is
necessary for the full responsiveness in the gene repression.
In fact, the inhibition of TGFβ1 gene by the PPARγ and RXR
heterodimer might account for either tumor suppression or
tumor promotion [18]. Also, as an eﬀort to identify the
molecular basis of TGFβ1 repression by PPARγ activators,
the eﬀects of PPARγ and RXR activation on the TGFβ1
gene transactivation, that is regulated by the proximal DNA
response elements, have been examined [18]. The potential
regulatory sites responsible for the TGFβ1 gene expression
have been explored by using the luciferase reporter gene
assays, which identiﬁed the putative PPREs located at the
multiplesitesupstreamfrom −453bpofthepromoterregion
[18]. Promoter deletion analyses indicate that neither the
putative PPREs nor the activator protein-1 (AP-1) binding
sites are directly regulated by PPARγ activators forthe gene
repression.
S6K1, a ubiquitous serine/threonine kinase, controls the
translational eﬃciency by phosphorylating ribosomal S6
protein [99]. S6K1 functions as a multifunctional kinase for
the phosphorylation of ribosomal S6 protein [99], CREM
[100], BAD [101], and the eukaryotic elongation factor 2
kinase [102]. Rapamycin, a well-known mammalian target
of rapamycin (mTOR) inhibitor, inhibited liver ﬁbrosis and
TGFβ1 expression in rats bile duct-ligated or challenged
with toxicants [103, 104], with a concomitant decrease
in S6K1 activity. It is well recognized that rapamycin
inhibits S6K1 activity via mTOR inhibition [105]. Yet, other
pharmacologicalagentsthatmodulateS6K1activityhavenot
beenreported.ThemechanismofPPARγ-RXRheterodimer-
mediated repression of the TGFβ1 gene has been elucidated
in terms of the modulation of S6K1 activity (Figure 2).
The PI3K-mTOR pathway regulates S6K1 for the reg-
ulation of transcription factors involved in the TGFβ1
gene transactivation. A study identiﬁed the inhibition of
S6K1 activity by the PPARγ-RXR, which contributes to
TGFβ1 gene repression [18]. Another signaling molecule,
PTEN, antagonizes the PI3-kinase-mTOR-S6K1-mediated
signalingcascade[106,107].Thus,ithasbeenelucidatedthat
PPARγ activators upregulate PTEN, which leads to the S6K1
inhibition, consequently causing TGFβ1 repression [18].
5. TRANSCRIPTION FACTORS RESPONSIBLE FOR
TGFβ REPRESSION BY PPARγ-RXR
In the promoter region of the TGFβ1g e n e( Figure 3),
the putative binding sites for PPARγ-RXR seemed to be
neither active nor responsible for the gene repression by
the activated PPARγ and RXR heterodimer. It has been
claimed that the eﬀects of PPARγ or retinoid ligands on
TGFβ1 gene expression might be mediated in part by AP-
1 inhibition [108, 109]. Nevertheless, such a result that
deletion of the DNA region containing both AP-1 sites still
had the capability to repress the gene by PPARγ activator
suggests that the AP-1 binding sites might not be a major
regulatory target in the TGFβ1 gene repression. Rather, the
target molecule altered by PPARγ-RXRα-activated cell signal
may be involved in the interaction with the protein recruited
on the AP-1 DNA complex. It appeared that the TGFβ1g e n e
repression may have not resulted from the direct inhibition
of AP-1, but other mechanistic basis [18].
Another study showed that the mechanism associated
with the inhibition of TGFβ1b yP P A R γ activators involves
theregulationofc-Fos[108].Inthestudy,thiazolidinediones
inhibit high-glucose-induced TGFβ1p r o m o t e ra c t i v i t y .A
suggested mechanism was raised based on the observation
that treatments of thiazolidinediones reduced high-glucose-
induced, activated PKC and c-Fos-mediated TGFβ1g e n e
expression in mesangial cells [108].
Zf9 as an immediate early gene reduces cell proliferation
with the induction of p21cip1 and the enhancement of c-
Jun degradation [110, 111], thus functioning as a poten-
tial tumor suppressor gene. The transcription factors that
interact with the known DNA binding sites on the regionChang Ho Lee et al. 5
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Figure 2: A schematic presentation of the multiple pathways regulated by PPARγ for tumor suppression, progression, inhibition of
metastasis, and cancer chemoprevention.
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Figure 3: The human TGFβ1 promoter region.
downstream within the −323bp of the TGFβ1 gene include
Zf9, NF1, and SP1. It is noteworthy that Zf9 activation
induces TGFβ1 during the activation of hepatic stellate
cells [112]. Also, Zf9 regulates TGFβ receptors and collagen
α1(I),promotingaccumulationofextracellularmatrix[113].
Studies have shown that Zf9 phosphorylation enhances its
nuclear localization and transcriptional activity [111]. Zf9 as
a transcription factor plays a crucial role for the induction
of TGFβ1[ 113]. Thus, phosphorylation status of Zf9 may
contribute to the promotion of its target gene expression
[114].IdentiﬁcationofthepartnersofZf9orphosphorylated
Zf9 for the TGFβ1 gene regulation and their molecular
interactions would be interesting to pursue. The constitutive
Zf9 phosphorylation by S6K1 strengthened the important
role of S6K1 as a multifunctional kinase for the transcription
factor regulation of target genes [100–102].
The TGFβ1 gene contains the DNA response element
interacting with Zf9 [16] that regulates multiple genes
involved in tissue diﬀerentiation. Activation of Zf9 includes
its phosphorylation at serine (or tyrosine) residues [114].
Thus, phosphorylation of Zf9 leads to transcription of its
target genes [111, 114]. Although the kinase catalyzing Zf9
phosphorylation has not been completely identiﬁed, the
inhibition ofZf9phosphorylationbyrapamycinthatinhibits
S6K1 activity via mTOR inhibition supports the role of
S6K1 in Zf9 phosphorylation [18]. More importantly, the
role of S6K1 in regulating TGFβ1 gene and the associated
molecular mechanistic basis have been clariﬁed in terms
of Zf9 dephosphorylation [18]. In view of the previous
observations that Zf9 is crucial as a transcription factor for
TGFβ1 induction in hepatic stellate cells [113] and that a
phosphorylatedformofZf9playsaroleinthetransactivation
of the target gene promoter [114], the potential ability of
PPARγ activators to inhibit serine phosphorylation of the
transcription factor has also been investigated. Thus, it has
been demonstrated that the inhibition of the TGFβ1g e n e
by the activation of PPARγ-RXR includes Zf9 dephospho-
rylation [18]. Therefore, TGFβ1 gene repression by PPARγ
activators appears to be related with dephosphorylation
of Zf9, supporting the conclusion that the PPARγ-RXR
heterodimer causes TGFβ1 repression via S6K1 inhibition,
and that the inhibition of S6K1 activity provides a central
mechanism, by which PPARγ-RXR regulates Zf9-dependent
TGFβ1 gene expression (Figure 2).6 PPAR Research
Moreover, it has been shown that PPARγ activation
induces PTEN, which serves as a PI(3,4,5)P3 lipid phos-
phatase and antagonizes PI3-kinase-mediated cell signaling
[106]. Functional PPREs located in the PTEN promoter
have been recognized [115]. The induction of PTEN by
PPARγ activators may result in TGFβ1 gene repression
following S6K1 inhibition. Furthermore, PPARγ activators
inhibited phosphorylations of Akt, ERK1/2, p90 ribosomal
S6 kinase-1 (RSK1), and mTOR, downstream of PTEN,
indicating that PTEN induction by PPARγ activators leads
to S6K1 inhibition via the pathways of ERK1/2-RSK1 as
well as Akt-mTOR. In conclusion, the result showing that
PPARγ activation upregulates PTEN, which has also been
implicatedintumor-inhibitoryoranti-inﬂammatoryactions
of PPARγ [106, 115], gives credence to the concept that
PPARγ activators induce PTEN during S6K1 inhibition,
and consequently causes TGFβ1 repression. Therefore, the
inhibition of tumor proliferation by PPARγ activators may
be explained in part by PPARγ-dependent TGFβ1 repression
(Figure 2), supporting the concept that the PPARγ activators
may be applied for controlling TGFβ1-induced cancer
metastasis and ﬁbrosis.
ACKNOWLEDGMENT
This workwassupported by theKorea Scienceand Engineer-
ing Foundation (KOSEF) grant funded by the Ministry of
Science and Technology (MOST), South Korean government
(no.R11-2007-107-01001-0).
REFERENCES
[1] R. A. Rahimi and E. B. Leof, “TGF-β signaling: a tale of two
responses,” Journal of Cellular Biochemistry, vol. 102, no. 3,
pp. 593–608, 2007.
[2] E. Piek, C.-H. Heldin, and P. T. Dijke, “Speciﬁcity, diversity,
and regulation in TGF-β superfamily signaling,” The FASEB
Journal, vol. 13, no. 15, pp. 2105–2124, 1999.
[ 3 ]A .B .R o b e r t sa n dM .B .S p o r n ,“ D i ﬀerential expression of
the TGF-β isoforms in embryogenesis suggests speciﬁc roles
in developing and adult tissues,” Molecular Reproduction and
Development, vol. 32, no. 2, pp. 91–98, 1992.
[4] M. H. Jarrar and A. Baranova, “PPARγ activation by
thiazolidinediones (TZDs) may modulate breast carcinoma
outcome: the importance of interplay with TGFβ signalling,”
Journal of Cellular and Molecular Medicine,v o l .1 1 ,n o .1 ,p p .
71–87, 2007.
[5] M. Fu, J. Zhang, X. Zhu, et al., “Peroxisome proliferator-
activated receptor γ inhibits transforming growth factor β-
inducedconnectivetissuegrowthfactorexpressioninhuman
aortic smooth muscle cells by interfering with Smad3,”
Journal of Biological Chemistry, vol. 276, no. 49, pp. 45888–
45894, 2001.
[6] W. Wang, F. Liu, and N. Chen, “Peroxisome proliferator-
activated receptor-γ (PPAR-γ) agonists attenuate the proﬁ-
brotic response induced by TGF-β1 in renal interstitial
ﬁbroblasts,” Mediators of Inﬂammation, vol. 2007, Article ID
62641, 7 pages, 2007.
[ 7 ]C .Z h a o ,W .C h e n ,L .Y a n g ,L .C h e n ,S .A .S t i m p s o n ,a n dA .
M. Diehl, “PPARγ agonists prevent TGFβ1/Smad3-signaling
in human hepatic stellate cells,” Biochemical and Biophysical
Research Communications, vol. 350, no. 2, pp. 385–391, 2006.
[8] Y. Li, X. Wen, B. C. Spataro, K. Hu, C. Dai, and Y. Liu,
“Hepatocyte growth factor is a downstream eﬀector that
mediates the antiﬁbrotic action of peroxisome proliferator-
activatedreceptor-γ agonists,”JournaloftheAmericanSociety
of Nephrology, vol. 17, no. 1, pp. 54–65, 2006.
[9] S. Zhou, S. Lechpammer, J. S. Greenberger, and J. Glowacki,
“Hypoxia inhibition of adipocytogenesis in human bone
marrow stromal cells requires transforming growth factor-
β/Smad3 signaling,” Journal of Biological Chemistry, vol. 280,
no. 24, pp. 22688–22696, 2005.
[10] X. Liang, T. Kanjanabuch, S.-L. Mao, et al., “Plasminogen
activator inhibitor-1 modulates adipocyte diﬀerentiation,”
American Journal of Physiology, vol. 290, no. 1, pp. E103–
E113, 2006.
[11] S. Redondo, E. Ruiz, C. G. Santos-Gallego, E. Padilla, and
T. Tejerina, “Pioglitazone induces vascular smooth muscle
cell apoptosis through a peroxisome proliferator-activated
receptor-γ, transforming growth factor-β1, and a Smad2-
dependent mechanism,” Diabetes, vol. 54, no. 3, pp. 811–817,
2005.
[12] B. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi,
andM.Haneda,“Peroxisomeproliferator-activatedreceptor-
γ ligands inhibit TGF-β1-induced ﬁbronectin expression in
glomerular mesangial cells,” Diabetes, vol. 53, no. 1, pp. 200–
208, 2004.
[ 1 3 ]J .H a n ,D .P .H a j j a r ,J .M .T a u r a s ,J .F e n g ,A .M .G o t t o
Jr., and A. C. Nicholson, “Transforming growth factor-β1
(TGF-β1) and TGF-β2 decrease expression of CD36, the
typeBscavengerreceptor,throughmitogen-activatedprotein
kinase phosphorylation of peroxisome proliferator-activated
receptor-γ,” Journal of Biological Chemistry, vol. 275, no. 2,
pp. 1241–1246, 2000.
[14] S. Ahdjoudj, K. Kaabeche, X. Holy, et al., “Transforming
growth factor-β inhibits CCAAT/enhancer-binding protein
expression and PPARγ activity in unloaded bone marrow
stromal cells,” Experimental Cell Research, vol. 303, no. 1, pp.
138–147, 2005.
[15] S. Zheng and A. Chen, “Disruption of transforming growth
factor-β signaling by curcumin induces gene expression of
peroxisome proliferator-activated receptor-γ in rat hepatic
stellate cells,” American Journal of Physiology, vol. 292, no. 1,
pp. G113–G123, 2007.
[ 1 6 ]S . - J .K i m ,A .G l i c k ,M .B .S p o r n ,a n dA .B .R o b e r t s ,
“Characterization of the promoter region of the human
transforming growth factor-β1g e n e , ”Journal of Biological
Chemistry, vol. 264, no. 1, pp. 402–408, 1989.
[17] R. ¨ Okl¨ u and R. Hesketh, “The latent transforming growth
factor β binding protein (LTBP) family,” Biochemical Journal,
vol. 352, part 3, pp. 601–610, 2000.
[18] S. J. Lee, E. K. Yang, and S. G. Kim, “Peroxisome proliferator-
activated receptor-γ and retinoic acid X receptor α represses
the TGFβ1 gene via PTEN-mediated p70 ribosomal S6
kinase-1 inhibition: role for Zf9 dephosphorylation,” Molec-
ular Pharmacology, vol. 70, no. 1, pp. 415–425, 2006.
[19] C. Weigert, K. Brodbeck, A. Bierhaus, H. U. H¨ aring, and
E. D. Schleicher, “c-Fos-driven transcriptional activation of
transforming growth factor β-1: inhibition of high glucose-
induced promoter activity by thiazolidinediones,” Biochemi-
cal and Biophysical Research Communications, vol. 304, no. 2,
pp. 301–307, 2003.Chang Ho Lee et al. 7
[20] Y. Inagaki, T. Nemoto, A. Nakao, et al., “Interaction between
GC Box binding factors and Smad proteins modulates cell
lineage-speciﬁc α2(I) collagen gene transcription,” Journal of
BiologicalChemistry,vol.276,no.19,pp.16573–16579,2001.
[21] Y. Inagaki, M. Mamura, Y. Kanamaru, et al., “Constitutive
phosphorylation and nuclear localization of Smad3 are
correlated with increased collagen gene transcription in
activated hepatic stellate cells,” Journal of Cellular Physiology,
vol. 187, no. 1, pp. 117–123, 2001.
[22] J. Massagu´ e and Y.-G. Chen, “Controlling TGF-β signaling,”
Genes and Development, vol. 14, no. 6, pp. 627–644, 2000.
[23] E. Piek, W. J. Ju, J. Heyer, et al., “Functional characterization
of transforming growth factor β signaling in Smad2- and
Smad3-deﬁcient ﬁbroblasts,” Journal of Biological Chemistry,
vol. 276, no. 23, pp. 19945–19953, 2001.
[24] J. L. Wrana, “Regulation of Smad activity,” Cell, vol. 100, no.
2, pp. 189–192, 2000.
[25] L. Vindevoghel, R. J. Lechleider, A. Kon, et al., “SMAD3/4-
dependent transcriptional activation of the human type VII
collagen gene (COL7A1) promoter by transforming growth
factor β,” Proceedings of the National Academy of Sciences of
theUnitedStatesofAmerica,vol.95,no.25,pp.14769–14774,
1998.
[26] X.-H. Feng, X. Lin, and R. Derynck, “Smad2, Smad3 and
Smad4 cooperate with Sp1 to induce p15Ink4B transcription
in response to TGF-β,” The EMBO Journal, vol. 19, no. 19,
pp. 5178–5193, 2000.
[27] S. Dennler, S. Itoh, D. Vivien, P. ten Dijke, S. Huet, and
J.-M. Gauthier, “Direct binding of Smad3 and Smad4 to
critical TGFβ-inducible elements in the promoter of human
plasminogen activator inhibitor-type 1 gene,” The EMBO
Journal, vol. 17, no. 11, pp. 3091–3100, 1998.
[28] R. S. Frey and K. M. Mulder, “Involvement of extracel-
lular signal-regulated kinase 2 and stress-activated protein
kinase/Jun N-terminal kinase activation by transforming
growth factor β in the negative growth control of breast
cancer cells,” Cancer Research, vol. 57, no. 4, pp. 628–633,
1997.
[29] H. Watanabe, M. P. de Caestecker, and Y. Yamada, “Tran-
scriptional cross-talk between Smad, ERK1/2, and p38
mitogen-activated protein kinase pathways regulates trans-
forming growth factor-β-induced aggrecan gene expression
in chondrogenic ATDC5 cells,” Journal of Biological Chem-
istry, vol. 276, no. 17, pp. 14466–14473, 2001.
[30] T. Hayashida, M. Decaestecker, and H. W. Schnaper, “Cross-
talk between ERK MAP kinase and Smad signaling pathways
enhances TGF-beta-dependent responses in human mesan-
gial cells,” The FASEB Journal, vol. 17, no. 11, pp. 1576–1578,
2003.
[31] F. Furukawa, K. Matsuzaki, S. Mori, et al., “p38 MAPK
mediates ﬁbrogenic signal through Smad3 phosphorylation
in rat myoﬁbroblasts,” Hepatology, vol. 38, no. 4, pp. 879–
889, 2003.
[ 3 2 ]M .U e m u r a ,E .S .S w e n s o n ,M .D .A .G a c ¸ a ,F .J .G i o r d a n o ,
M .R e i s s ,a n dR .G .W e l l s ,“ S m a d 2a n dS m a d 3p l a yd i ﬀerent
rolesinrathepaticstellatecellfunctionandα-smoothmuscle
actin organization,” Molecular Biology of the Cell, vol. 16, no.
9, pp. 4214–4224, 2005.
[33] X. Liu, W. Wang, H. Hu, et al., “Smad3 speciﬁc inhibitor,
naringenin, decreases the expression of extracellular matrix
induced by TGF-β1 in cultured rat hepatic stellate cells,”
Pharmaceutical Research, vol. 23, no. 1, pp. 82–89, 2006.
[34] K.W .Kang,Y .G.Kim,M.K.Cho,etal.,“Oltiprazregenerates
cirrhotic liver through CCAAT/enhancer binding protein-
mediated stellate cell inactivation,” The FASEB Journal, vol.
16, no. 14, pp. 1988–1990, 2002.
[35] R. S. Muraoka-Cook, N. Dumont, and C. L. Arteaga,
“Dual role of transforming growth factor β in mammary
tumorigenesis and metastatic progression,” Clinical Cancer
Research, vol. 11, no. 2, pp. 937s–943s, 2005.
[36] R. Derynck, R. J. Akhurst, and A. Balmain, “TGF-β signaling
intumorsuppressionandcancerprogression,”Nature Genet-
ics, vol. 29, no. 2, pp. 117–129, 2001.
[37] M. J. Truty and R. Urrutia, “Basics of TGF-β and pancreatic
cancer,” Pancreatology, vol. 7, no. 5-6, pp. 423–435, 2007.
[38] G.J.HannonandD.Beach,“p15INK4B isapotentialeﬀectorof
TGF-β-induced cell cycle arrest,” Nature, vol. 371, no. 6494,
pp. 257–261, 1994.
[39] M. B. Datto, Y. Li, J. F. Panus, D. J. Howe, Y. Xiong, and X.-
F. Wang, “Transforming growth factor β induces the cyclin-
dependent kinase inhibitor p21 through a p53-independent
mechanism,” Proceedings of the National Academy of Sciences
oftheUnitedStatesofAmerica,vol.92,no.12,pp.5545–5549,
1995.
[40] J. A. Pietenpol, J. T. Holt, R. W. Stein, and H. L. Moses,
“Transforming growth factor β1 suppression of c-myc gene
transcription: role in inhibition of keratinocyte prolifera-
tion,” Proceedings of the National Academy of Sciences of the
UnitedStatesofAmerica,vol.87,no.10,pp.3758–3762,1990.
[41] M. G. Alexandrow, M. Kawabata, M. Aakre, and H. L.
Moses, “Overexpression of the c-myc oncoprotein blocks the
growth-inhibitory response but is required for the mitogenic
eﬀects of transforming growth factor β1,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 92, no. 8, pp. 3239–3243, 1995.
[42] Y. Kang, C.-R. Chen, and J. Massagu´ e, “A self-enabling TGFβ
response coupled to stress signaling: Smad engages stress
response factor ATF3 for Id1 repression in epithelial cells,”
Molecular Cell, vol. 11, no. 4, pp. 915–926, 2003.
[43] P. M. Siegel and J. Massagu´ e, “Cytostatic and apoptotic
actions of TGF-β in homeostasis and cancer,” Nature Reviews
Cancer, vol. 3, no. 11, pp. 807–820, 2003.
[44] S.G.Kim,H.-S.Jong,T.-Y.Kim,etal.,“Transforminggrowth
factor-β1 induces apoptosis through Fas ligand-independent
activation of the Fas death pathway in human gastric SNU-
620carcinomacells,”MolecularBiologyoftheCell,vol.15,no.
2, pp. 420–434, 2004.
[45] J. E. Chipuk, M. Bhat, A. Y. Hsing, J. Ma, and D.
Danielpour, “Bcl-xL blocks transforming growth factor-
β1-induced apoptosis by inhibiting cytochrome c release
and not by directly antagonizing Apaf-1-dependent caspase
activation in prostate epithelial cells,” Journal of Biological
Chemistry, vol. 276, no. 28, pp. 26614–26621, 2001.
[46] A. M. Arias, “Epithelial mesenchymal interactions in cancer
and development,” Cell, vol. 105, no. 4, pp. 425–431, 2001.
[47] J. P. Thiery, “Epithelial-mesenchymal transitions in tumour
progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–
454, 2002.
[48] H. Hugo, M. L. Ackland, T. Blick, et al., “Epithelial-
mesenchymal and mesenchymal-epithelial transitions in
carcinoma progression,” Journal of Cellular Physiology, vol.
213, no. 2, pp. 374–383, 2007.
[ 4 9 ]A .G a l ,T .S j ¨ oblom, L. Fedorova, S. Imreh, H. Beug, and A.
Moustakas, “Sustained TGFβ exposure suppresses Smad and
non-Smad signalling in mammary epithelial cells, leading8 PPAR Research
to EMT and inhibition of growth arrest and apoptosis,”
Oncogene, vol. 27, no. 9, pp. 1218–1230, 2008.
[50] K. Pardali and A. Moustakas, “Actions of TGF-β as tumor
suppressor and pro-metastatic factor in human cancer,”
Biochimica et Biophysica Acta, vol. 1775, no. 1, pp. 21–62,
2007.
[51] D. Medici, E. D. Hay, and D. A. Goodenough, “Cooperation
between snail and LEF-1 transcription factors is essential for
TGF-β1-induced epithelial-mesenchymal transition,” Molec-
ular Biology of the Cell, vol. 17, no. 4, pp. 1871–1879, 2006.
[52] L. Van Aelst and M. Symons, “Role of Rho family GTPases in
epithelial morphogenesis,” Genes and Development, vol. 16,
no. 9, pp. 1032–1054, 2002.
[53] M. A. Friese, J. Wischhusen, W. Wick, et al., “RNA inter-
ference targeting transforming growth factor-β enhances
NKG2D-mediated antiglioma immune response, inhibits
glioma cell migration and invasiveness, and abrogates
tumorigenicity in vivo,” Cancer Research, vol. 64, no. 20, pp.
7596–7603, 2004.
[54] R. Coras, A. H¨ olsken, S. Seufert, et al., “The peroxisome
proliferator-activatedreceptor-γ agonisttroglitazoneinhibits
transforming growth factor-β-mediated glioma cell migra-
tion and brain invasion,” Molecular Cancer Therapeutics, vol.
6, no. 6, pp. 1745–1754, 2007.
[55] S.-K. Leivonen, R. Ala-aho, K. Koli, R. Gr´ enman, J. Peltonen,
and V.-M. K¨ ah¨ ari, “Activation of Smad signaling enhances
collagenase-3 (MMP-13) expression and invasion of head
and neck squamous carcinoma cells,” Oncogene, vol. 25, no.
18, pp. 2588–2600, 2006.
[56] S.-K. Leivonen and V.-M. K¨ ah¨ ari, “Transforming growth
factor-β signaling in cancer invasion and metastasis,” Inter-
national Journal of Cancer, vol. 121, no. 10, pp. 2119–2124,
2007.
[57] M. Deckers, M. van Dinther, J. Buijs, et al., “The tumor
suppressor Smad4 is required for transforming growth factor
β-induced epithelial to mesenchymal transition and bone
metastasisofbreastcancercells,” CancerResearch,vol.66,no.
4, pp. 2202–2209, 2006.
[58] Y. Kang, W. He, S. Tulley, et al., “Breast cancer bone metas-
tasis mediated by the Smad tumor suppressor pathway,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 102, no. 39, pp. 13909–13914, 2005.
[59] W. Wick, M. Platten, and M. Weller, “Glioma cell invasion:
regulation of metalloproteinase activity by TGF-β,” Journal
of Neuro-Oncology, vol. 53, no. 2, pp. 177–185, 2001.
[60] H. K. Rooprai, G. J. Rucklidge, C. Panou, and G. J.
Pilkington, “The eﬀects of exogenous growth factors on
matrix metalloproteinase secretion by human brain tumour
cells,”BritishJournalofCancer,vol.82,no.1,pp.52–55,2000.
[61] N. Johansson, R. Ala-aho, V. Uitto, et al., “Expression of
collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by
transformedkeratinocytesisdependentontheactivityofp38
mitogen-activatedproteinkinase,”Journal of Cell Science,vol.
113, no. 2, pp. 227–235, 2000.
[62] S.-W. Lin, M.-T. Lee, F.-C. Ke, et al., “TGF β1s t i m u l a t e s
the secretion of matrix metalloproteinase 2 (MMP2) and the
invasive behavior in human ovarian cancer cells, which is
suppressed by MMP inhibitor BB3103,” Clinical & Experi-
mental Metastasis, vol. 18, no. 6, pp. 493–499, 2000.
[63] K. Giehl, Y. Imamichi, and A. Menke, “Smad4-independent
TGF-β signaling in tumor cell migration,” Cells Tissues
Organs, vol. 185, no. 1–3, pp. 123–130, 2007.
[64] M. O. Li, Y. Y. Wan, S. Sanjabi, A.-K. L. Robertson, and
R. A. Flavell, “Transforming growth factor-β regulation of
immune responses,” Annual Review of Immunology, vol. 24,
pp. 99–146, 2006.
[65] J.H.Kehrl,L.M.Wakeﬁeld, A.B.Roberts,etal., “Production
of transforming growth factor β by human T lymphocytes
and its potential role in the regulation of T cell growth,”
Journal of Experimental Medicine, vol. 163, no. 5, pp. 1037–
1050, 1986.
[ 6 6 ]A .M a ,R .K o k a ,a n dP .B u r k e t t ,“ D i v e r s ef u n c t i o n so fI L - 2 ,
IL-15, and IL-7 in lymphoid homeostasis,” Annual Review of
Immunology, vol. 24, pp. 657–679, 2006.
[67] S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell, “Transforming
growth factor-β and the immune response: implications for
anticancer therapy,” Clinical Cancer Research, vol. 13, no. 18,
pp. 5262–5270, 2007.
[ 6 8 ]M .A h m a d z a d e ha n dS .A .R o s e n b e r g ,“ T G F - β1 attenuates
the acquisition and expression of eﬀector function by tumor
antigen-speciﬁc human memory CD8 T cells,” Journal of
Immunology, vol. 174, no. 9, pp. 5215–5223, 2005.
[ 6 9 ]A .H .R o o k ,J .H .K e h r l ,L .M .W a k e ﬁ e l d ,e ta l . ,“ E ﬀects of
transforming growth factor β on the functions of natural
killer cells: depressed cytolytic activity and blunting of
interferon responsiveness,” Journal of Immunology, vol. 136,
no. 10, pp. 3916–3920, 1986.
[70] G. Bellone, M. Aste-Amezaga, G. Trinchieri, and U. Rodeck,
“Regulation of NK cell functions by TGF-β1,” Journal of
Immunology, vol. 155, no. 3, pp. 1066–1073, 1995.
[71] F. Geissmann, P. Revy, A. Regnault, et al., “TGF-β1 prevents
the noncognate maturation of human dendritic Langerhans
cells,” Journal of Immunology, vol. 162, no. 8, pp. 4567–4575,
1999.
[72] C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineo-
plastic eﬀects of peroxisome proliferator-activated receptor γ
agonists,” Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004.
[73] G. D. Girnun, W. M. Smith, S. Drori, et al., “APC-dependent
suppression of colon carcinogenesis by PPARγ,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 99, no. 21, pp. 13771–13776, 2002.
[74] T.Ikezoe,C.W.Miller,S.Kawano,etal.,“Mutationalanalysis
of the peroxisome proliferator-activated receptor γ in human
malignancies,” Cancer Research, vol. 61, no. 13, pp. 5307–
5310, 2001.
[ 7 5 ]P .S a r r a f ,E .M u e l l e r ,W .M .S m i t h ,e ta l . ,“ L o s s - o f - f u n c t i o n
mutations in PPARγ associated with human colon cancer,”
Molecular Cell, vol. 3, no. 6, pp. 799–804, 1999.
[76] T. Kubota, K. Koshizuka, E. A. Williamson, et al., “Ligand for
peroxisome proliferator-activated receptor γ (troglitazone)
has potent antitumor eﬀect against human prostate cancer
both in vitro and in vivo,” Cancer Research, vol. 58, no. 15,
pp. 3344–3352, 1998.
[ 7 7 ]G .G .C h e n ,J .F .L e e ,S .H .W a n g ,U .P .F .C h a n ,P .C .I p ,a n d
W. Y. Lau, “Apoptosis induced by activation of peroxisome-
proliferator activated receptor-gamma is associated with Bcl-
2 and Nf-κB in human colon cancer,” Life Sciences, vol. 70,
no. 22, pp. 2631–2646, 2002.
[78] J .A.Br ockman,R.A.G upta,andR.N.Dubois,“ A ctivationof
PPARγ leads to inhibition of anchorage-independent growth
of human colorectal cancer cells,” Gastroenterology, vol. 115,
no. 5, pp. 1049–1055, 1998.
[79] M. Kato, T. Kusumi, S. Tsuchida, M. Tanaka, M. Sasaki,
and H. Kudo, “Induction of diﬀerentiation and peroxisome
proliferator-activated receptor γ expression in colon cancerChang Ho Lee et al. 9
cell lines by troglitazone,” Journal of Cancer Research and
Clinical Oncology, vol. 130, no. 2, pp. 73–79, 2004.
[80] K. Ohta, T. Endo, K. Haraguchi, J. M. Hershman, and T.
Onaya,“Ligandsforperoxisomeproliferator-activatedrecep-
torγ inhibitgrowthandinduceapoptosisofhumanpapillary
thyroid carcinoma cells,” Journal of Clinical Endocrinology
and Metabolism, vol. 86, no. 5, pp. 2170–2177, 2001.
[ 8 1 ]P .S a r r a f ,E .M u e l l e r ,D .J o n e s ,e ta l . ,“ D i ﬀerentiation and
reversal of malignant changes in colon cancer through
PPARγ,” Nature Medicine, vol. 4, no. 9, pp. 1046–1052, 1998.
[82] J. Yu, L. Qiao, L. Zimmermann, et al., “Troglitazone inhibits
tumor growth in hepatocellular carcinoma in vitro and in
vivo,” Hepatology, vol. 43, no. 1, pp. 134–143, 2006.
[83] A. P. Heaney, M. Fernando, and S. Melmed, “PPAR-γ
receptor ligands: novel therapy for pituitary adenomas,”
Journal of Clinical Investigation, vol. 111, no. 9, pp. 1381–
1388, 2003.
[84] C. Day, “Thiazolidinediones: a new class of antidiabetic
drugs,” Diabetic Medicine, vol. 16, no. 3, pp. 179–192, 1999.
[85] J.-R. Weng, C.-Y. Chen, J. J. Pinzone, M. D. Ringel, and C.-
S. Chen, “Beyond peroxisome proliferator-activated receptor
γ signaling: the multi-facets of the antitumor eﬀect of
thiazolidinediones,” Endocrine-Related Cancer, vol. 13, no. 2,
pp. 401–413, 2006.
[86] S.S.Palakurthi,H.Aktas,L.M.Grubissich,R.M.Mortensen,
and J. A. Halperin, “Anticancer eﬀects of thiazolidinediones
are independent of peroxisome proliferator-activated recep-
tor γ and mediated by inhibition of translation initiation,”
Cancer Research, vol. 61, no. 16, pp. 6213–6218, 2001.
[87] M.-A. Bae and B. J. Song, “Critical role of c-Jun N-terminal
protein kinase activation in troglitazone-induced apoptosis
of human HepG2 hepatoma cells,” Molecular Pharmacology,
vol. 63, no. 2, pp. 401–408, 2003.
[88] S. J. Baek, L. C. Wilson, L. C. Hsi, and T. E. Eling, “Troglita-
zone,apero xisomeproliferator -activatedreceptorγ (PPARγ)
ligand, selectively induces the early growth response-1 gene
independently of PPARγ: a novel mechanism for its anti-
tumorigenic activity,” Journal of Biological Chemistry, vol.
278, no. 8, pp. 5845–5853, 2003.
[89] A.Sugimura,Y.Kiriyama,H.Nochi,etal.,“Troglitazonesup-
presses cell growth of myeloid leukemia cell lines by induc-
tion of p21WAF1/CIP1 cyclin-dependent kinase inhibitor,”
Biochemical and Biophysical Research Communications, vol.
261, no. 3, pp. 833–837, 1999.
[90] A.-M. Lefebvre, I. Chen, P. Desreumaux, et al., “Activation
of the peroxisome proliferator-activated receptor γ promotes
the development of colon tumors in C57BL/6J-APC
Min/+
mice,” Nature Medicine, vol. 4, no. 9, pp. 1053–1057, 1998.
[91] E. Saez, J. Rosenfeld, A. Livolsi, et al., “PPARγ signaling
exacerbatesmammaryglandtumordevelopment,”Genesand
Development, vol. 18, no. 5, pp. 528–540, 2004.
[92] E. Y. Park, I. J. Cho, and S. G. Kim, “Transactivation of the
PPAR-responsive enhancer module in chemopreventive glu-
tathione S-transferase gene by the peroxisome proliferator-
activated receptor-γ and retinoid X receptor heterodimer,”
Cancer Research, vol. 64, no. 10, pp. 3701–3713, 2004.
[93] F.-S. Chou, P.-S. Wang, S. Kulp, and J. J. Pinzone, “Eﬀects
of thiazolidinediones on diﬀerentiation, proliferation, and
apoptosis,” Molecular Cancer Research, vol. 5, no. 6, pp. 523–
530, 2007.
[94] E. A. Thompson, “PPARγ physiology and pathology in
gastrointestinal epithelial cells,” Molecules and Cells, vol. 24,
no. 2, pp. 167–176, 2007.
[95] Y. Kodera, K. Takeyama, A. Murayama, M. Suzawa, Y.
Masuhiro, and S. Kato, “Ligand type-speciﬁc interactions of
peroxisome proliferator-activated receptor γ with transcrip-
tional coactivators,” Journal of Biological Chemistry, vol. 275,
no. 43, pp. 33201–33204, 2000.
[ 9 6 ] K .W .K a n g ,I .J .C h o ,C .H .L e e ,a n dS .G .K i m ,
“Essential role of phosphatidylinositol 3-kinase-dependent
CCAAT/enhancer binding protein β activation in the induc-
tion of glutathione S-transferase by oltipraz,” Journal of the
National Cancer Institute, vol. 95, no. 1, pp. 53–66, 2003.
[ 9 7 ] K .W .K a n g ,E .Y .P a r k ,a n dS .G .K i m ,“ A c t i v a t i o n
of CCAAT/enhancer-binding protein β by 2 -amino-3 -
methoxyﬂavone (PD98059) leads to the induction of glu-
tathione S-transferase A2,” Carcinogenesis,v o l .2 4 ,n o .3 ,p p .
475–482, 2003.
[98] S. M. A. Holmbeck, H. J. Dyson, and P. E. Wright, “DNA-
inducedconformationalchangesarethebasisforcooperative
dimerization by the DNA binding domain of the retinoid X
receptor,” Journal of Molecular Biology, vol. 284, no. 3, pp.
533–539, 1998.
[99] P. Jen¨ o, L. M. Ballou, I. Novak-Hofer, and G. Thomas,
“Identiﬁcation and characterization of a mitogen-activated
S6 kinase,” Proceedings of the National Academy of Sciences of
theUnitedStatesofAmerica,vol.85,no.2,pp.406–410,1988.
[100] R. P. de Groot, L. M. Ballou, and P. Sassone-Corsi, “Positive
regulation of the cAMP-responsive activator CREM by the
p70 S6 kinase: an alternative route to mitogen-induced gene
expression,” Cell, vol. 79, no. 1, pp. 81–91, 1994.
[101] H. Harada, J. S. Andersen, M. Mann, N. Terada, and S.
J. Korsmeyer, “p70S6 kinase signals cell survival as well
as growth, inactivating the pro-apoptotic molecule BAD,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 98, no. 17, pp. 9666–9670, 2001.
[102] X. Wang, W. Li, M. Williams, N. Terada, D. R. Alessi, and
C. G. Proud, “Regulation of elongation factor 2 kinase by
p90RSK1 and p70 S6 kinase,” The EMBO Journal, vol. 20, no.
16, pp. 4370–4379, 2001.
[103] J. Zhu, J. Wu, E. Frizell, et al., “Rapamycin inhibits hepatic
stellate cell proliferation in vitro and limits ﬁbrogenesis in an
in vivo model of liver ﬁbrosis,” Gastroenterology, vol. 117, no.
5, pp. 1198–1204, 1999.
[104] E. Biecker, A. De Gottardi, M. Neef, et al., “Long-term treat-
ment of bile duct-ligated rats with rapamycin (sirolimus)
signiﬁcantly attenuates liver ﬁbrosis: analysis of the underly-
ing mechanisms,” Journal of Pharmacology and Experimental
Therapeutics, vol. 313, no. 3, pp. 952–961, 2005.
[105] D. M. Sabatini, H. Erdjument-Bromage, M. Lui, P. Tempst,
a n dS .H .S n y d e r ,“ R A F T 1 :am a m m a l i a np r o t e i nt h a t
binds to FKBP12 in a rapamycin-dependent fashion and is
homologous to yeast TORs,” Cell, vol. 78, no. 1, pp. 35–43,
1994.
[106] K. S. Lee, S. J. Park, P. H. Hwang, et al., “PPAR-gamma
modulates allergic inﬂammation through up-regulation of
PTEN,” The FASEB Journal, vol. 19, no. 8, pp. 1033–1035,
2005.
[107] J.-L. Liu, X. Sheng, Z. K. Hortobagyi, Z. Mao, G. E. Gallick,
and W. K. A. Yung, “Nuclear PTEN-mediated growth sup-
pression is independent of Akt down-regulation,” Molecular
and Cellular Biology, vol. 25, no. 14, pp. 6211–6224, 2005.
[108] C. Weigert, K. Brodbeck, A. Bierhaus, H. U. H¨ aring, and
E. D. Schleicher, “c-Fos-driven transcriptional activation
of transforming growth factor β-1: inhibition of high10 PPAR Research
glucose-induced promoter activity by thiazolidinediones,”
Biochemical and Biophysical Research Communications, vol.
304, no. 2, pp. 301–307, 2003.
[109] G. Salbert, A. Fanjul, F. J. Piedraﬁta, et al., “Retinoic
acid receptors and retinoid X receptor-α down-regulate the
transforming growth factor-β1 promoter by antagonizing
AP-1 activity,” Molecular Endocrinology, vol. 7, no. 10, pp.
1347–1356, 1993.
[110] G. Narla, K. E. Heath, H. L. Reeves, et al., “KLF6, a candidate
tumor suppressor gene mutated in prostate cancer,” Science,
vol. 294, no. 5551, pp. 2563–2566, 2001.
[111] D.A.Slavin,N.P.Koritschoner,C.C.Prieto,F.J.L´ opez-D´ ıaz,
B. Chatton, and J. L. Bocco, “A new role for the Kr¨ uppel-
like transcription factor KLF6 as an inhibitor of c-Jun proto-
oncoprotein function,” Oncogene, vol. 23, no. 50, pp. 8196–
8205, 2004.
[112] V. Ratziu, A. Lalazar, L. Wong, et al., “Zf9, a Kruppel-like
transcriptionfactorup-regulatedinvivoduringearlyhepatic
ﬁbrosis,”ProceedingsoftheNationalAcademyofSciencesofthe
UnitedStatesofAmerica,vol.95,no.16,pp.9500–9505,1998.
[113] Y. Kim, V. Ratziu, S.-G. Choi, et al., “Transcriptional activa-
tion of transforming growth factor β1 and its receptors by
the Kruppel-like factor Zf9/core promoter-binding protein
and Sp1: potential mechanisms for autocrine ﬁbrogenesis in
response to injury,” Journal of Biological Chemistry, vol. 273,
no. 50, pp. 33750–33758, 1998.
[114] V. G. Warke, M. P. Nambiar, S. Krishnan, et al., “Tran-
scriptional activation of the human inducible nitric-oxide
synthase promoter by Kr¨ uppel-like factor 6,” Journal of
BiologicalChemistry,vol.278,no.17,pp.14812–14819,2003.
[115] L. Patel, I. Pass, P. Coxon, C. P. Downes, S. A. Smith, and
C. H. Macphee, “Tumor suppressor and anti-inﬂammatory
actions of PPARγ agonists are mediated via upregulation of
PTEN,” Current Biology, vol. 11, no. 10, pp. 764–768, 2001.